Home · Medications · Compounded tirzepatide
Medication guide · compounded tirzepatideWhat is compounded tirzepatide? Legal status, safety and cost in 2026
Compounded tirzepatide is a version of tirzepatide — the active ingredient in Eli Lilly's Zepbound and Mounjaro — mixed by a compounding pharmacy for an individual patient instead of being made by Lilly. As of October 14, 2026 it is not FDA-approved: the FDA does not review it for safety, effectiveness or quality before it is sold. Since the tirzepatide shortage ended (December 19, 2024), state-licensed 503A pharmacies may not compound essentially a copy of it regularly or in inordinate amounts, except where a prescriber documents a clinically significant difference for the patient; online programs charge roughly $69–$434 a month depending on dose and conditions versus $299–$449 a month for brand Zepbound vials from LillyDirect.
Compounded tirzepatide vs Zepbound and Mounjaro
| Compounded tirzepatide | Zepbound / Mounjaro (brand) | |
|---|---|---|
| FDA approval | Not approved; no premarket review | Approved (Zepbound for chronic weight management and moderate-to-severe obstructive sleep apnea with obesity; Mounjaro for type 2 diabetes) |
| Made by | A 503A compounding pharmacy (patient-specific) | Eli Lilly and Company |
| Clinical-trial evidence | None for the compounded product itself | SURMOUNT and SURPASS programs; SURMOUNT-1: 20.9% mean weight loss at 72 weeks on 15 mg (treatment-regimen estimand) |
| Typical self-pay price | $69–$349 a month online, depending on conditions | Zepbound vials $299 (2.5 mg), $399 (5 mg), $449 (7.5–15 mg with refill within 45 days) via LillyDirect |
| Added ingredients | Sometimes B12, glycine, B6 or niacinamide | None |
| Who checks quality | State board of pharmacy (503A); FDA for 503B facilities | FDA manufacturing oversight |
The molecule is the same name, but the product is not the same: dose strength, formulation, sterility testing and the source of the active ingredient depend on the pharmacy. The FDA has warned that some compounders use salt forms (for example semaglutide sodium or semaglutide acetate) that it considers different active ingredients with no lawful basis for compounding.
Is compounded tirzepatide legal in 2026?
Legal, with narrow conditions. The timeline that matters:
- December 19, 2024 — the FDA determined the tirzepatide injection shortage was resolved.
- February 18, 2025 / March 19, 2025 — end of the FDA's grace period for 503A pharmacies and 503B outsourcing facilities to keep compounding as if a shortage existed. After that, a 503A pharmacy may not regularly compound "essentially a copy" of an approved drug unless the prescriber documents a significant difference for that patient.
- March 3, 2026 — the FDA warned 30 telehealth companies about marketing that implied compounded GLP-1s were the same as approved drugs.
- April 1, 2026 — the FDA said semaglutide combined with another ingredient, such as vitamin B12, at strengths within 10% of an approved product can still be considered essentially a copy, with no action against 503A pharmacies filling four or fewer such prescriptions a month.
- April 30, 2026 — the FDA proposed to keep tirzepatide, semaglutide and liraglutide off the 503B bulks list. Comments closed July 30, 2026; as of October 14, 2026 no final decision had been published.
- September 18, 2026 — warning letter to Empower Pharmacy naming tirzepatide/niacinamide as appearing to be essentially a copy (our analysis).
Is compounded tirzepatide safe?
The FDA cannot vouch for it either way, because it does not review compounded drugs before sale. Its concerns page (updated October 1, 2026) lists more than 730 adverse-event reports associated with compounded tirzepatide as of May 31, 2026, along with dosing errors from multi-dose vials and products using unapproved salt forms. Quality problems also show up in inspections: a January 16, 2026 warning letter to Boothwyn Pharmacy described a tirzepatide/glycine/methylcobalamin injection that failed sterility testing. Side effects of tirzepatide itself — nausea, diarrhea, constipation, vomiting, and rarer risks such as pancreatitis and gallbladder disease — apply to any version. See tirzepatide side effects.
What compounded tirzepatide costs online
As of October 14, 2026 the verified programs in our price index print figures from $69 a month (Collective, plus a $199 yearly membership) to $349 (Henry Meds, oral); outside the index, Remedy Meds charges $399 per 4 weeks and Midi Health up to $434. NexLife, our #1 pick, charges $169 month to month or $139 a month on a 12-month plan, the same at every dose. Check four things before comparing stickers: whether the price rises with dose, membership or consult fees, first-month promotions, and prepaid terms. Brand Zepbound costs more but is FDA-approved: see Zepbound vs compounded over 12 months.
Why some compounded tirzepatide contains B12, glycine or niacinamide
Some pharmacies add vitamins or amino acids. A February 2026 review in the Annals of Pharmacotherapy found "little justification for adding nutrients," and Eli Lilly said in March 2026 that it found an impurity formed when tirzepatide reacts with B12. The FDA has said adding B12 to semaglutide does not by itself make it lawful to compound routinely, and applied similar reasoning to tirzepatide/niacinamide in September 2026. Full explainer: B12, glycine and niacinamide in compounded tirzepatide.
How to choose a compounded tirzepatide program
- The program names the dispensing pharmacy before you pay, and you can find its license (see pharmacy profiles).
- A licensed clinician reviews your history, contraindications and current medications — not just a checkout form.
- The price is stated for your maintenance dose, with fees and refund rules in writing.
- The program does not call the product "generic Zepbound" or say it is the same as an approved drug.
- There is a plan if the FDA's 503B decision or a pharmacy problem interrupts supply.
More: how to verify a telehealth provider · red flags · 2026 rankings.
Frequently asked questions
Is compounded tirzepatide the same as Zepbound?
No. It contains the same active ingredient but is made by a compounding pharmacy, is not FDA-approved and has no clinical-trial data of its own. Zepbound is Eli Lilly's FDA-approved product.
Is compounded tirzepatide still available in 2026?
Yes, from 503A pharmacies on patient-specific prescriptions, within the limits the FDA has set since the shortage ended. The FDA's proposal to keep tirzepatide off the 503B bulks list was not final as of October 14, 2026.
Why is compounded tirzepatide cheaper than Zepbound?
It skips FDA approval costs and brand pricing. Online programs bundle the drug with the clinician visit and shipping for about $69–$434 a month, versus $299–$449 a month for Zepbound vials from LillyDirect.
Does compounded tirzepatide work as well as Zepbound?
There are no head-to-head trials. The weight-loss figures people quote, such as 20.9% at 72 weeks in SURMOUNT-1, come from Lilly's FDA-approved product and cannot be assumed for a compounded version.
What is compounded tirzepatide on Reddit usually about?
Mostly price, which pharmacy filled a prescription, and side effects. Treat individual posts as anecdotes; check a pharmacy's FDA record on our pharmacy pages.
Sources
- FDA: Policies for compounders as national GLP-1 supply stabilizes (updated April 1, 2026)
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (current as of October 1, 2026)
- FDA: Compounding and the FDA — questions and answers
- FDA: Proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list (April 30, 2026)
- Federal Register: comment period extended to July 30, 2026
- FDA: Warning letters to 30 telehealth companies (March 3, 2026)
- FDA warning letter 738238 to Empower Pharmacy (September 18, 2026)
- FDA warning letter to Boothwyn Pharmacy (January 16, 2026)
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1), NEJM 2022
- LillyDirect: Zepbound self-pay pricing
Informational only, not medical advice. Compounded drugs are not FDA-approved and are not the same products as Mounjaro® or Zepbound® (trademarks of Eli Lilly and Company). Prices and policies were read on the companies' own pages on the date shown and can change.